Drug profile · INN
enfortumab vedotin-ejfv
PADCEV
enfortumab vedotin-ejfv (PADCEV) is a nectin-4 binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — enfortumab vedotin-ejfv
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
enfortumab vedotin-ejfv (PADCEV) is a nectin-4 binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Nectin-4 binding agent
Primary target: Nectin-4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is enfortumab vedotin-ejfv?
enfortumab vedotin-ejfv (PADCEV) is a nectin-4 binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for enfortumab vedotin-ejfv?
PADCEV is a marketed brand name for enfortumab vedotin-ejfv. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of enfortumab vedotin-ejfv?
enfortumab vedotin-ejfv has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.